Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib in ALK-positive NSCLC with brain metastases or leptomeningeal disease
NL-OMON47423Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceritinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Nov 2015; status: active, not recruiting.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47423.